Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy.
Acne
Cyproterone acetate/ethinylestradiol
Diane-35
Prescribing
Real world data
Risk minimization
Journal
Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
23
04
2020
accepted:
18
05
2020
pubmed:
30
5
2020
medline:
21
9
2021
entrez:
30
5
2020
Statut:
ppublish
Résumé
To study the effect of risk minimization measures taken in 2013 for cyproterone acetate/ethinylestradiol (CPA/EE) on initiation, concomitant use of other hormonal contraceptives (HC) and potential indications. This retrospective study included data on CPA/EE use in 2011-2017 from the Netherlands, UK, and Italy. The initiation rate of CPA/EE decreased by 44%-91% between 2011 and 2017. Proportions with concomitant use of other HC (<3%) and approved indications did not change over time. Apart from a strong reduction in CPA/EE use following risk minimization measures, no major changes were observed regarding concomitant use of other HC or potential reasons for use.
Identifiants
pubmed: 32470466
pii: S0010-7824(20)30158-X
doi: 10.1016/j.contraception.2020.05.010
pii:
doi:
Substances chimiques
Drug Combinations
0
Ethinyl Estradiol
423D2T571U
Cyproterone Acetate
4KM2BN5JHF
Cyproterone acetate, ethinyl estradiol drug combination
60528-19-0
Cyproterone
E61Q31EK2F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
243-245Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.